SNSS Financial Facts

License and other revenue: 854K
Research and development: 6.3M
See Full Income Statement

Warrant liability: 1.77M
Accrued compensation: 1.25M
See Full Balance Sheet

Sunesis Pharmaceuticals Inc. (SNSS) Earnings

  |   Expand Research on SNSS
Next EPS Date 11/10/15 *Est. EPS Growth Rate +25.0% *Last Qtr.
Average EPS % Beat Rate +11.4% Revenue Growth Rate -57.3% *Last Qtr.
Average % Move 1-Wk after EPS +1.2% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
7/30/15 Q215 -$0.15-$0.13 -$0.02$854K$1.21M N/A Details
5/5/15 Q115 -$0.13-$0.16 +$0.03$854K$980K N/A Details
3/12/15 Q414 -$0.02-$0.19 +$0.17$896K$1.17M N/A Details
11/10/14 Q314 -$0.25-$0.17 -$0.08$854K$1.97M N/A Details
8/5/14 Q214 -$0.20-$0.17 -$0.03$2M$1.32M N/A Details
5/7/14 Q114 -$0.26-$0.17 -$0.09$2M$1.32M N/A Details
3/6/14 Q413 -$0.15-$0.20 +$0.05$2M$1.37M N/A Details
11/12/13 Q313 -$0.16-$0.20 +$0.04$1.99M$1.44M N/A Details